Surgery is an appropriate treatment option for men with bladder outlet obstruction (BOO) in whom pharmacotherapy has proven unsuccessful. Cost pressures and newer minimally invasive outlet procedures have led to a migration away from the traditional inpatient care setting toward ambulatory surgical centers. We previously demonstrated that patients undergoing BOO surgery in the inpatient setting experience higher rates of 30-day revisits compared to ambulatory procedures. In this context, we aimed to identify predictors of 30-day revisits and associated costs following BOO surgery.
INTRODUCTION AND OBJECTIVES:
Surgery is an appropriate treatment option for men with bladder outlet obstruction (BOO) in whom pharmacotherapy has proven unsuccessful. Cost pressures and newer minimally invasive outlet procedures have led to a migration away from the traditional inpatient care setting toward ambulatory surgical centers. We previously demonstrated that patients undergoing BOO surgery in the inpatient setting experience higher rates of 30-day revisits compared to ambulatory procedures. In this context, we aimed to identify predictors of 30-day revisits and associated costs following BOO surgery.
METHODS: All-payer data from the 2014 Healthcare Cost and Utilization Project (HCUP) State Databases from Florida (FL) and New York (NY) were used to identify all patients undergoing an index BOO procedure in the form of transurethral resection (TURP), laser/ photovaporization (PVP), or thermotherapy (TUMT/TUNA). Patient demographics, regional data, 30-day revisit rates, and total charges (converted to costs) associated with revisit were determined. Multivariate logistic regression adjusted for facility clustering was utilized to identify predictors of 30-day revisit.
RESULTS: Of the 15,094 patients undergoing a BOO procedure, 1,444 (9.6%) experienced a 30-day revisit at a median cost of $4263.43. The 30-day revisit rate for cases performed in the inpatient setting was significantly higher than ambulatory procedures (12.0% vs. 8.1%, P<0.001). Predictors of 30-day revisit included older age (OR 1.01, 95% CI 1.00-1.02; P[0.002), higher Charlson Comorbidity Index score (CCI !2 vs. 0: OR 1.75, 95% CI 1.49-2.04; P<0.001), payer status (private vs. Medicare: OR 0.77, 95% CI 0.62-0.95; P[0.02), median household income (!$66,000 vs. <$40,000: OR 0.72, 95% CI 0.57-0.93; P[0.004), and index care setting (ambulatory vs. inpatient: OR 0.48, 95% CI 0.40-0.57; P<0.001).
CONCLUSIONS: We demonstrated that index care setting and payer status are independent predictors of 30-day revisit following BOO, with patients undergoing BOO surgery in the inpatient setting and those with Medicare experiencing higher revisit rates. Our findings have important policy implications in the setting of recent value-based purchasing efforts, which seek to reduce variation in non-clinical sources of perioperative costs and outcomes. 
MP01-20 AN IN-VITRO STUDY OF HYBRID LASER FOR PROSTATE SURGERY
Mark Taratkin*, Dmitry Enikeev, Petr Glybochko, Leonid Rapoport, Moscow, Russian Federation; Christopher Netsch, Benedikt Becker, Andreas J. Gross, Hamburg, Germany INTRODUCTION AND OBJECTIVES: The interactions between the laser and tissue depend on the wavelength of the laser. Lasers affect the tissue via its relevant chromophores that absorb energy. In the prostate they are water for Ho:YAG, Tm:YAG and Tm-fiber lasers (TFL) and haemoglobin for the Greenlight (KTP) laser and blue diode laser (BDL). Combining the two lasers (TFLþBDL) with different target chromophores (water and hemoglobin) may have potential benefits for prostate surgery, namely less carbonization and faster vaporization. The aim of this study was to investigate the potential of a hybrid (TFLþBDL) laser vs. TFL and Ho:YAG lasers in vitro.
METHODS: Fresh non-frozen porcine kidney was used as the model for the prostate to compare 3 lasers with an average power of 120W: a Ho:YAG laser, a TFL and a hybrid TFLþBDL (Table 1) . In all cases, a 600 µm cleaved laser fiber was employed. A motorized XY translation stage with fixed fiber holder for control of cutting speed (2mm/s and 5 mm/s) was used. All samples were put in tissue holders with 0.5AE0.1 mm gap between the fiber and tissue. Five incisions of kidney in saline solution with each laser were made. Lactate dehydrogenase (LDH) staining of the embedded specimens was performed to determine incision depth, zones of vaporization, zones of coagulation and visible carbonization rate (from 0 to 3).
RESULTS: Laser properties, laser settings and pathology results are shown in Table 1 . Hybrid laser (TFLþBDL) produced the deepest incisions and provided the fastest vaporization among the investigated lasers with little to no carbonization and limited coagulation depth. All these facts make it a perfect tool for tissue vaporization.
CONCLUSIONS: A hybrid TFL þ BDL makes deeper and faster incisions than TFL and Ho:YAG lasers. Interestingly, it also produces a smaller carbonization zone and limits coagulation depth.
